Clinical Trials Logo

Arthritis clinical trials

View clinical trials related to Arthritis.

Filter by:

NCT ID: NCT00655824 Terminated - Clinical trials for Arthritis, Rheumatoid

Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403

Start date: January 1, 2008
Phase: Phase 2
Study type: Interventional

A 3-year open-label trial for patients who previously participated in Trial Hx-CD20-403 and who fulfill the eligibility criteria for this trial (GEN413) . Th e primary purpose of the trial is to evaluate the long-term effectiveness of repeated courses ( a maximum of 9 treatment courses) of ofatumumab in RA patients who previously received ofatumumab or placebo in Trial Hx-CD20-403.

NCT ID: NCT00654368 Completed - Clinical trials for Rheumatoid Arthritis

CAMEO: Canadian Methotrexate and Etanercept Outcome Study

Start date: June 2008
Phase: Phase 4
Study type: Interventional

The purpose of the study is to evaluate the use of etanercept in the treatment of rheumatoid arthritis with or without methotrexate treatment over a 24 month period

NCT ID: NCT00650767 Completed - Clinical trials for Rheumatoid Arthritis

A Study of ARRY-438162 in Patients With Rheumatoid Arthritis

Start date: March 2008
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-438162 in treating rheumatoid arthritis in patients on stable doses of methotrexate, and to further evaluate the safety of the study drug. Approximately 200 patients from the US, Argentina, Brazil, Hungary, Peru, Poland and Romania will be enrolled in this study.

NCT ID: NCT00650455 Completed - Clinical trials for Arthritis, Rheumatoid

Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients

Start date: February 2003
Phase: Phase 4
Study type: Interventional

The objectives of the study were to evaluate the efficacy, safety, and tolerability of valdecoxib 10 mg once daily (QD) or naproxen 500 mg twice daily (BID) versus placebo, and to assess the efficacy of valdecoxib 10 mg QD versus naproxen 500 mg BID, in treating the signs and symptoms of rheumatoid arthritis (RA) in a severe Rheumatoid Arthritis population.

NCT ID: NCT00650156 Completed - Clinical trials for Rheumatoid Arthritis

Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis

Start date: June 2007
Phase: Phase 1
Study type: Interventional

Pharmacokinetic and Safety Study with Adalimumab in Chinese Subjects with Mild Rheumatoid Arthritis

NCT ID: NCT00650078 Completed - Clinical trials for Rheumatoid Arthritis

Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis

CAPRA-2
Start date: March 2008
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the safety and efficacy, with regards to the signs and symptoms, of MR prednisone (Lodotra®) versus placebo in combination with standard Disease Modifying Anti-Rheumatic Drug (DMARD) treatment in patients with active rheumatoid arthritis.

NCT ID: NCT00650026 Approved for marketing - Clinical trials for Rheumatoid Arthritis

Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis

ReAct
Start date: n/a
Phase: N/A
Study type: Expanded Access

Multicenter Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Active Rheumatoid Arthritis

NCT ID: NCT00649922 Completed - Clinical trials for Rheumatoid Arthritis

Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis

Start date: October 2003
Phase: Phase 4
Study type: Interventional

To evaluate the immunogeneicity of the Influenza virus and standard 23-valent pneumococcal virus in subject with RA receiving adalimumab or placebo

NCT ID: NCT00649545 Approved for marketing - Clinical trials for Rheumatoid Arthritis

Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis

CanAct
Start date: n/a
Phase: N/A
Study type: Expanded Access

The primary objective of this study is to assess the safety (by collecting adverse events and serious adverse events) of adalimumab administered every other week to patients with moderately to severly active rheumatoid arthritis who have failed prior disease-modifying anti-rheumatic drugs (DMARDs).

NCT ID: NCT00647920 Completed - Clinical trials for Rheumatoid Arthritis

Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

Start date: July 2003
Phase: Phase 3
Study type: Interventional

A Randomized, Double-Blind, Placebo-Controlled, Study of the Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated with Methotrexate